Geneva Health Forum

7th Edition: Precision Global Health in the Digital Age

10-12 April 2018
Geneva, Switzerland
Bernard Pécoul, Executive Director – plenary talk on emerging infectious diseases crisis
Digas Ngolo, Investigator Coordinator, DNDi Africa – parallel session on ehealth

AFRAVIH 2018

4-7 April 2018
Bordeaux, France

Isabelle Andrieux-Meyer, Head of Clinical Development, Paediatric HIV/HCV Programmes – panel discussion on HIV and side session on ravidasvir-sofosbuvir results

18th International Congress on Infectious Diseases

1-4 March 2018
Buenos Aires, Argentina
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation on Chagas disease
Byron Arana, Head of Cutaneous Leishmaniasis, DNDi – parallel symposium on cutaneous leishmaniasis
Graciela Diap, Paediatric HIV/HCV, DNDi, and Francisco Viegas Neves da Silva, Regional Policy Advocacy Consultant, DNDi Latin America – parallel symposium on hepatitis C

3rd National Hepatitis Symposium 2018

1-2 March 2018
Kuala Lumpur, Malaysia
Jean Michel Piedagenel, Head of DNDi South East Asia Regional Office, Malaysia – panel discussion on access to hepatitis treatment
François Simon, Clinial Trial Leader Paediatric HIV/HCV, DNDi, Switzerland – expert talk on clinical trials

DNDi reçoit le Prix 2017 de l’Innovation à Genève pour récompenser son action en faveur des populations les plus négligées

A l’occasion de l’Evénement économique 2017 du 9 novembre dernier, la Chambre de commerce, d’industrie et des services de Genève (CCIG), le Département de la sécurité et de l’économie (DSE) et l’Office de Promotion des Industries et des Technologies (OPI) ont décerné le Prix 2017 de l’innovation à l’initiative Médicaments contre les Maladies Négligées (DNDi).

DNDi celebra la iniciativa de Malasia para asegurar el acceso al tratamientos más asequibles para la hepatitis C

[Kuala Lumpur, Ginebra – 20 de septiembre de 2017]
Malasia ha emitido una licencia de “uso gubernamental” que permite acceder a versiones más baratas de un medicamento costoso y patentado para tratar la hepatitis C. Esta decisión histórica ayudará a más de 400.000 personas que viven con hepatitis C en Malasia a acceder al sofosbuvir y podría tener importantes repercusiones en el esfuerzo global para asegurar el acceso a costosos tratamientos para esta enfermedad viral.
[Bahasa] [English] [Português]

DNDi celebra iniciativa da Malásia para garantir o acesso a tratamentos mais baratos para a hepatite C

[Kuala Lumpur, Genebra – 20 de setembro de 2017]
A Malásia emitiu uma licença de “uso governamental” que permite o acesso a versões mais baratas de um medicamento caro e patenteado para o tratamento da hepatite C. Essa decisão histórica deve ajudar as mais de 400 mil pessoas vivendo com hepatite C na Malásia a ter acesso ao sofosbuvir, podendo ter repercussões importantes no esforço global que é feito para garantir o acesso a caros tratamentos para esta doença.
[Bahasa] [English] [Español]

 

DNDi welcomes Malaysia’s move to secure access to more affordable treatments for hepatitis C

[Kuala Lumpur, Geneva20 September 2017]
Malaysia has issued a “government use” licence enabling access to more affordable versions of an expensive and patented medicine to treat hepatitis C. This landmark decision should help the more than 400,000 people living with hepatitis C in Malaysia access sofosbuvir, and could have important repercussions in the global effort to secure access to expensive treatments for this viral disease.
[Bahasa] [Español] [Português]

DNDi sambut baik usaha Malaysia untuk mendapatkan akses kepada kos rawatan lebih rendah untuk hepatitis C

[Kuala Lumpur, Geneva20 September 2017]
Malaysia telah mengeluarkan lesen “kegunaan kerajaan” yang membolehkan akses kepada ubat yang mahal dan berpaten pada harga yang lebih rendah untuk merawat hepatitis C. Keputusan penting ini pastinya akan membantu lebih daripada 400,000 orang penghidap hepatitis C di Malaysia mendapatkan ubat sofosbuvir dan akan memberi kesan yang signifikan dalam usaha global untuk mendapat akses kepada rawatan yang mahal bagi penyakit yang disebabkan virus ini.“Kerajaan Malaysia tidak dapat menyediakan akses kepada rejimen rawatan yang mampu dibayar oleh masyarakat umum kerana harga sofosbuvir yang sangat mahal di Malaysia,” kata YB Datuk Seri Dr S. Subramaniam, Menteri Kesihatan Malaysia.
[English] [Español] [Português]